Share on StockTwits

Albany Molecular Research (NASDAQ:AMRI) Director Ambra Thomas E. Phd D sold 20,000 shares of the company’s stock in a transaction dated Monday, August 11th. The shares were sold at an average price of $18.99, for a total value of $379,800.00. Following the completion of the sale, the director now directly owns 2,801,879 shares of the company’s stock, valued at approximately $53,207,682. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

AMRI has been the subject of a number of recent research reports. Analysts at Zacks downgraded shares of Albany Molecular Research from an “outperform” rating to a “neutral” rating in a research note on Tuesday. They now have a $23.70 price target on the stock. Separately, analysts at Morgan Stanley reiterated an “underperform” rating on shares of Albany Molecular Research in a research note on Monday, July 7th. They now have a $15.00 price target on the stock, up previously from $13.00. Finally, analysts at Sterne Agee reiterated an “underperform” rating on shares of Albany Molecular Research in a research note on Monday, July 7th. They now have a $15.00 price target on the stock, up previously from $13.00.

Albany Molecular Research (NASDAQ:AMRI) traded up 1.26% during mid-day trading on Wednesday, hitting $19.36. 196,688 shares of the company’s stock traded hands. Albany Molecular Research has a 52 week low of $9.71 and a 52 week high of $22.30. The stock has a 50-day moving average of $20.09 and a 200-day moving average of $16.97. The company has a market cap of $600.8 million and a price-to-earnings ratio of 38.39.

Albany Molecular Research (NASDAQ:AMRI) last announced its earnings results on Tuesday, August 5th. The company reported $0.22 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.20 by $0.02. The company had revenue of $68.20 million for the quarter, compared to the consensus estimate of $65.64 million. Analysts expect that Albany Molecular Research will post $0.91 EPS for the current fiscal year.

Albany Molecular Research, Inc (NASDAQ:AMRI) is a contract research and manufacturing company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.